Boundless Bio shares surge 15.32% premarket as FDA accepts BBI-940 IND and extends cash runway through 2028.

Boundless Bio (NASDAQ:BOLD) surged 15.32% in premarket trading following the FDA’s acceptance of its IND application for BBI-940, a first-in-class oral kinesin degrader targeting extrachromosomal DNA-driven cancers. The approval enables the initiation of KOMODO-1, a first-in-human trial for metastatic breast cancer, expected to begin in H1 2026. The company also announced the discontinuation of its Phase 1/2 POTENTIATE trial (BBI-355 + BBI-825) to prioritize resources on BBI-940, extending its cash runway into H2 2028. These updates underscore progress in its core pipeline and improved capital efficiency, aligning with the stock’s bullish premarket reaction.